Loading...
•
Sep 30, 2023
Milestone Pharmaceuticals Q3 2023 Earnings Report
Reported financial results for the third quarter and provided a clinical and corporate update.
Key Takeaways
Milestone Pharmaceuticals reported its Q3 2023 financial results, highlighting the submission of the New Drug Application for CARDAMYST and positive results from the Phase 2 study evaluating etripamil for AFib-RVR.
Submitted New Drug Application for CARDAMYST in treating PSVT.
Released positive results from Phase 2 study evaluating etripamil to treat patients with AFib-RVR.
Approaching 2024 with a well-defined strategy.
Etripamil has the potential to help people living with serious heart arrythmias.
Forward Guidance
Milestone Pharmaceuticals is focused on the development and commercialization of innovative cardiovascular medicines, with etripamil as its lead product candidate.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...